{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T14:19:33Z","timestamp":1779373173551,"version":"3.53.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Meropenem is a broad-spectrum carbapenem antibiotic with mostly renal excretion. Conflicting data are available regarding meropenem pharmacokinetics in critically ill neonates on concomitant continuous renal replacement therapy (CRRT) and\/or extracorporeal membrane oxygenation (ECMO). Our objectives were to assess meropenem clearance in a neonate on CRRT and ECMO, compare it to previously published data and assess whether dose recommendations can be generalized in this population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case description:<\/jats:title>\n            <jats:p>A 2.5\u2009kg male infant with a large diaphragmatic hernia was delivered by cesarean section at week 35 and immediately mechanically ventilated due to shock and respiratory insufficiency. He underwent surgical correction of the hernia, but developed recurrent sepsis, multiorgan failure and pulmonary hypertension. He remained mechanically ventilated and required ECMO and continuous venovenous hemodiafiltration. He was started on meropenem 40\u2009mg\/kg\/dose, every 8 hs for Enterobacter cloacae bacteremia and sepsis, but due to lack of clinical and microbiologic response despite in vitro susceptibility, he was started on a continuous meropenem infusion of 240\u2009mg\/kg\/d, based on dose recommendations in a similar case. We measured steady state meropenem plasma concentrations on 2 occasions, during ECMO and continuous venovenous hemodiafiltration (CVVHDF) and then on CVVHDF only.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Meropenem serum concentrations were 90 and 64\u2009mg\/L on the first and second occasion (therapeutic target concentration, 10\u2009mg\/L) corresponding to a clearance of 1.9 and 2.6\u2009mL\/kg\/min. This clearance estimate was substantially lower than that reported in toddlers on CRRT and ECMO in some studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>In neonates and infants, meropenem clearance is difficult to predict because of dynamic ontogenetic changes in renal function. This problem is further aggravated in acutely ill infants with decreased renal function, renal replacement therapy and\/or ECMO. Therefore, Target Concentration Intervention based on meropenem plasma concentrations is indispensable to ensure therapeutic exposure in this population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003354","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T12:42:11Z","timestamp":1640868131000},"page":"117-120","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Individual Meropenem Clearance in Infants on ECMO and CVVHDF is Difficult to Predict"],"prefix":"10.1097","volume":"41","author":[{"given":"Ali","family":"Jabareen","sequence":"first","affiliation":[{"name":"Pharmacy Services, Rambam Health Care Campus, Haifa, Israel"},{"name":"Clinical Pharmacology Unit, Section of Clinical Pharmacology and Toxicology, Rambam Health Care Campus, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Nassar","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, Section of Clinical Pharmacology and Toxicology, Rambam Health Care Campus, Haifa, Israel"},{"name":"Rappaport Faculty of Medicine, Technion \u2013 Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Karasik","sequence":"additional","affiliation":[{"name":"Toxicology and Pharmacology Laboratory, Section of Clinical Pharmacology and Toxicology, Rambam Health Care Campus, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna","family":"Efrati","sequence":"additional","affiliation":[{"name":"Toxicology and Pharmacology Laboratory, Section of Clinical Pharmacology and Toxicology, Rambam Health Care Campus, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Hadash","sequence":"additional","affiliation":[{"name":"Pediatric Intensive Care Unit, Ruth Rappaport Children\u2019s Hospital, Rambam Health Care Campus, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Kassis","sequence":"additional","affiliation":[{"name":"Rappaport Faculty of Medicine, Technion \u2013 Israel Institute of Technology, Haifa, Israel"},{"name":"Pediatric Intensive Care Unit, Ruth Rappaport Children\u2019s Hospital, Rambam Health Care Campus, Haifa, Israel"},{"name":"Pediatric Infectious Diseases Unit, Ruth Rappaport Children\u2019s Hospital, Rambam Health Care Campus, Haifa, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kurnik","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, Section of Clinical Pharmacology and Toxicology, Rambam Health Care Campus, Haifa, Israel"},{"name":"Rappaport Faculty of Medicine, Technion \u2013 Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"R1-20250615","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2050-6511-15-21","article-title":"Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients.","volume":"15","author":"Goncalves-Pereira","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"R2-20250615","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/AAC.39.8.1721","article-title":"Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children.","volume":"39","author":"Blumer","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"R3-20250615","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1128\/AAC.00712-15","article-title":"Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.","volume":"59","author":"Ulldemolins","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 9","key":"R4-20250615","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.2042-7158.1998.tb02396.x","article-title":"Pharmacokinetics of meropenem in intensive care patients receiving continuous renal replacement therapy.","volume":"50","author":"Giles","year":"1998","journal-title":"J Pharm Pharmacol"},{"key":"R4a-20250615","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00228-019-02761-7","article-title":"Population pharmacokinetics of meropenem in critically ill children with different renal functions.","volume":"76","author":"Rapp","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 5","key":"R5-20250615","doi-asserted-by":"crossref","first-page":"S642","DOI":"10.21037\/jtd.2017.11.02","article-title":"Drugs pharmacokinetics during veno-venous extracorporeal membrane oxygenation in pediatrics.","volume":"10","author":"Di Nardo","year":"2018","journal-title":"J Thorac Dis"},{"key":"R6-20250615","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/jac\/dks435","article-title":"Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern?","volume":"68","author":"Shekar","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R7-20250615","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.clinthera.2016.07.169","article-title":"Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation: a review of the current literature.","volume":"38","author":"Sherwin","year":"2016","journal-title":"Clin Ther"},{"key":"R8-20250615","first-page":"92","article-title":"Pharmacokinetics of continuous infusion meropenem with concurrent extracorporeal life support and continuous renal replacement therapy: a case report.","volume":"21","author":"Cies","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R9-20250615","first-page":"1018","article-title":"Therapeutic drug monitoring for meropenem after the extracorporeal membrane oxygenation circuit change in children: is it necessary?","volume":"82","author":"Di Nardo","year":"2016","journal-title":"Minerva Anestesiol"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1002\/phar.1476","article-title":"Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support.","volume":"34","author":"Cies","year":"2014","journal-title":"Pharmacotherapy"},{"key":"R12-20250615","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/jcpt.13344","article-title":"Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: a prospective observational study.","volume":"46","author":"Wang","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"R13-20250615","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1186\/s13054-014-0565-2","article-title":"The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.","volume":"18","author":"Shekar","year":"2014","journal-title":"Crit Care"},{"key":"R15-20250615","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s40262-015-0266-2","article-title":"Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.","volume":"54","author":"Pai","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"R18-20250615","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2133\/dmpk.DMPK-11-RG-027","article-title":"Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic\/pharmacodynamic considerations.","volume":"26","author":"Ohata","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"R19-20250615","first-page":"e00760","article-title":"Reappraisal of the optimal dose of meropenem in critically ill infants and children: a developmental pharmacokinetic-pharmacodynamic analysis.","volume":"64","author":"Wang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-20250615","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/jcph.1798","article-title":"Optimal dosing of meropenem in a small cohort of critically ill children receiving continuous renal replacement therapy.","volume":"61","author":"Tan","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"R21-20250615","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/0018578718779009","article-title":"Stability of meropenem after reconstitution for administration by prolonged infusion.","volume":"54","author":"Fawaz","year":"2019","journal-title":"Hosp Pharm"},{"key":"R22-20250615","first-page":"276","article-title":"Population pharmacokinetics and pharmacodynamic target attainment of meropenem in critically ill young children.","volume":"22","author":"Cies","year":"2017","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R23-20250615","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jgar.2020.04.029","article-title":"Meropenem pharmacokinetics during extracorporeal membrane oxygenation and continuous haemodialysis: a case report.","volume":"22","author":"Saito","year":"2020","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:02:34Z","timestamp":1750003354000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003354"}},"subtitle":["A Case Report and Review of the Literature"],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003354","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,28]]}}}